These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38223613)

  • 1. Therapeutic outcome of dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
    Hu C; Qu T; Li L; Huang Y; Liu H; Rao C
    Afr Health Sci; 2023 Jun; 23(2):416-421. PubMed ID: 38223613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ginger supplementation for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
    Zhou Q; Peng Y; Chen F; Dai J
    Afr Health Sci; 2023 Mar; 23(1):614-621. PubMed ID: 37545930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of dapagliflozin for type 1 diabetes: a meta-analysis of randomized controlled studies.
    Ma J; Zhao Y; Fan H; Liu J
    Afr Health Sci; 2021 Mar; 21(1):1-7. PubMed ID: 34394274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Aso Y; Kato K; Sakurai S; Kishi H; Shimizu M; Jojima T; Iijima T; Maejima Y; Shimomura K; Usui I
    Int J Clin Pract; 2019 May; 73(5):e13335. PubMed ID: 30810254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of dapagliflozin in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Sun L; Deng C; Gu Y; He Y; Yang L; Shi J
    Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101876. PubMed ID: 35321843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease.
    Phrueksotsai S; Pinyopornpanish K; Euathrongchit J; Leerapun A; Phrommintikul A; Buranapin S; Chattipakorn N; Thongsawat S
    J Gastroenterol Hepatol; 2021 Oct; 36(10):2952-2959. PubMed ID: 34129252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empagliflozin for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
    Tang X; Zhang H; Wang X; Yang D
    Afr Health Sci; 2022 Sep; 22(3):391-398. PubMed ID: 36910362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study.
    Eriksson JW; Lundkvist P; Jansson PA; Johansson L; Kvarnström M; Moris L; Miliotis T; Forsberg GB; Risérus U; Lind L; Oscarsson J
    Diabetologia; 2018 Sep; 61(9):1923-1934. PubMed ID: 29971527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Shimizu M; Suzuki K; Kato K; Jojima T; Iijima T; Murohisa T; Iijima M; Takekawa H; Usui I; Hiraishi H; Aso Y
    Diabetes Obes Metab; 2019 Feb; 21(2):285-292. PubMed ID: 30178600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Feng M; Lv H; Xu X; Wang J; Lyu W; Fu S
    Medicine (Baltimore); 2019 Jul; 98(30):e16575. PubMed ID: 31348290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soy diet for nonalcoholic fatty liver disease: A meta-analysis of randomized controlled trials.
    Xiong P; Zhu YF
    Medicine (Baltimore); 2021 Jun; 100(22):e25817. PubMed ID: 34087824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of glucagon-like peptide-1 receptor agonists on fat accumulation in patients with diabetes mellitus and non-alcoholic fatty liver disease or obesity: A systematic review and meta-analysis of randomized control trials.
    Xie W; Hong Z; Li B; Huang B; Dong S; Cai Y; Ruan L; Xu Q; Mou L; Zhang Y
    J Diabetes Complications; 2024 Jun; 38(6):108743. PubMed ID: 38688179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dapagliflozin for nonalcoholic fatty liver disease: A systematic review and meta-analysis.
    He K; Li J; Xi W; Ge J; Sun J; Jing Z
    Diabetes Res Clin Pract; 2022 Mar; 185():109791. PubMed ID: 35202771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
    Zhu Y; Xu J; Zhang D; Mu X; Shi Y; Chen S; Wu Z; Li S
    Front Endocrinol (Lausanne); 2021; 12():769069. PubMed ID: 34956080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study.
    Kinoshita T; Shimoda M; Nakashima K; Fushimi Y; Hirata Y; Tanabe A; Tatsumi F; Hirukawa H; Sanada J; Kohara K; Irie S; Kimura T; Nakamura Y; Nishioka M; Obata A; Nakanishi S; Mune T; Kaku K; Kaneto H
    J Diabetes Investig; 2020 Nov; 11(6):1612-1622. PubMed ID: 32329963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Nowrouzi-Sohrabi P; Rezaei S; Jalali M; Ashourpour M; Ahmadipour A; Keshavarz P; Akbari H
    Eur J Pharmacol; 2021 Feb; 893():173823. PubMed ID: 33352183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum high-molecular-weight adiponectin and response to dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Aso Y; Sagara M; Niitani T; Kato K; Iijima T; Tomaru T; Jojima T; Usui I
    J Investig Med; 2021 Oct; 69(7):1324-1329. PubMed ID: 34016738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
    Zhang M; Zhang L; Wu B; Song H; An Z; Li S
    Diabetes Metab Res Rev; 2014 Mar; 30(3):204-21. PubMed ID: 24115369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Favorable effect of sodium-glucose cotransporter 2 inhibitor, dapagliflozin, on non-alcoholic fatty liver disease compared with pioglitazone.
    Cho KY; Nakamura A; Omori K; Takase T; Miya A; Yamamoto K; Nomoto H; Kameda H; Taneda S; Kurihara Y; Aoki S; Atsumi T; Miyoshi H
    J Diabetes Investig; 2021 Jul; 12(7):1272-1277. PubMed ID: 33131199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
    Xing B; Zhao Y; Dong B; Zhou Y; Lv W; Zhao W
    J Diabetes Investig; 2020 Sep; 11(5):1238-1247. PubMed ID: 32083798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.